

# A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

NCT07086105

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Adze Biotechnology Australia Pty Ltd
Enrollment	30 participants

## Plain Language Summary

---

This study is testing a new experimental treatment called Adze1.C in people with advanced melanoma (a serious type of skin cancer) that has spread and cannot be surgically removed. This is an early-phase study to assess safety and early signs of effectiveness.

**\*\*You may be eligible if...\*\***

- You are 18 or older
- You have been diagnosed with unresectable Stage IIIB to IV metastatic melanoma confirmed by biopsy
- Your cancer has not responded to, or you are not a candidate for, standard treatment options
- You are in good enough health for treatment (ECOG 0 or 1)
- Your cancer has measurable tumor lesions

**\*\*You may NOT be eligible if...\*\***

- You have uncontrolled infections or other serious active illnesses
- You have active autoimmune disease
- You have had certain prior treatments that disqualify participation
- You are pregnant or breastfeeding

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (7)

- Male or female participants aged 18 years or older at Screening.
- Histologically confirmed unresectable Stage IIIB to IV metastatic melanoma.
- Refractory to, or unsuitable for, standard treatment options as determined by the investigator.
- Not a suitable candidate for curative resection.
- Presence of measurable disease per iRECIST (excluding irradiated lesions unless progression post-radiation is documented).
- ... and 2 more (see full listing online)

### Exclusion (16)

- Uncontrolled intercurrent illness, including but not limited to:
- Active systemic infection or fever  $\geq 38^{\circ}\text{C}$  within 5 days prior to Screening
- Symptomatic congestive heart failure
- NYHA Class III or IV heart failure
- Unstable angina or arrhythmia
- ... and 11 more (see full listing online)

---

## Locations (3 total)

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://ClinicalTrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).

The Queen Elizabeth Hospital, Adelaide, South Australia, Australia  
Tasman Oncology Research, Southport, Queensland, Australia  
Monash Health, Clayton, Victoria, Australia

---

<https://clinicaltrials.gov/study/NCT07086105>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).